Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin

Imesch P, Patrick Imesch, Samartzis EP, Eleftherios Pierre Samartzis, Eleftherios P Samartzis, Schneider M, Michael Schneider, Fink D, Daniel Fink, André Fedier
Fertility and sterility · 2011 · vol. 95(5) , pp. 1579–1583 · doi:10.1016/j.fertnstert.2010.12.058 · PMID:21295294 · W2102610819
Lab / animal OA: closed CC0 ⤵ 34 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Romidepsin treatment inhibited transcription, expression, and secretion of vascular epithelial growth factor (VEGF) in human epithelial endometriotic cells.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To investigate whether the histone deacetylase (HDAC) inhibitor romidepsin down-regulates VEGF (vascular endothelial growth factor) gene expression and abrogates VEGF protein secretion in human epithelial endometriotic cells. DESIGN: In vitro study with human immortalized epithelial endometriotic cells. SETTING: University hospital. PATIENT(S): Not applicable. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Real-time reverse-transcriptase polymerase chain reaction to evaluate VEGF gene expression, immunoblot analysis to evaluate protein expression, and enzyme-linked immunosorbent assay to evaluate VEGF protein secretion into the culture medium. RESULT(S): Treatment of 11z human endometriotic cells with romidepsin statistically significantly inhibited VEGF gene transcription and down-regulated VEGF protein expression. Moreover, romidepsin abrogated the secretion of VEGF protein into the culture medium. Romidepsin also reduced the expression of hypoxia-inducible factor-1α (HIF-1α), which is implicated in the transcription of the VEGF gene, in cobalt chloride-pretreated (to mimic hypoxic conditions) 11z cultures. CONCLUSION(S): Romidepsin targets VEGF at the transcriptional level, which subsequently leads to the reduction of secreted VEGF (the "active" form of VEGF). Therefore, romidepsin may be a potential therapeutic candidate against angiogenesis in endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Depsipeptides Endometriosis Epithelial Cells Peritoneal Diseases Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A Angiogenesis Inhibitors Angiogenesis Inhibitors Angiogenesis Inhibitors Antibiotics, Antineoplastic Antibiotics, Antineoplastic Antibiotics, Antineoplastic Cell Line, Transformed Cell Line, Transformed Depsipeptides Depsipeptides Dose-Response Relationship, Drug Dose-Response Relationship, Drug Down-Regulation Down-Regulation

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (37)

Cited by (34)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:08:38.374512+00:00
unpaywall
last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0 · commercial use OK